NCT05392751View on ClinicalTrials.gov

Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

April 24, 2024

Study Completion Date

April 24, 2024

Conditions
Retinitis PigmentosaRetinitis Pigmentosa Syndrome
Interventions
DRUG

EA-2353

EA-2353 Ophthalmic Suspension

Trial Locations (5)

33136

Endogena Site 005, Miami

48109

Endogena Site 003, Ann Arbor

75231

Endogena Site 002, Dallas

78503

Endogena Site 001, McAllen

97232

Endogena Site 004, Portland

Sponsors
All Listed Sponsors
lead

Endogena Therapeutics, Inc

INDUSTRY